Table 3.
Associations between baseline levels of proteins in patients and controls and hazard ratios for any failure from univariate Cox analysis. All expression values are log2 transformations of absolute levels in ng/L.
| Protein | Patients vs controls |
Hazard ratio Abnormal vs normal levels |
Hazard ratio Abnormal vs normal levels Excluding intermediates |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients (n = 86) Median (min, max) |
Controls (n = 15) Median (min, max) |
p-Value | Group size (n/n) | HR | 95% CI | p-Value | Group size (n/n) | HR | 95% CI | p-Value | |||
| EGFR | 15.7 | (4.2; 19.1) | 15.1 | (13.8; 15.9) | 0.03* | 41/45 | 0.81 | (0.35;1.84) | 0.61 | 28/31 | 1.03 | (0.62; 1.71) | 0.92 |
| Leptin | 13.4 | (8.1; 16.0) | 13.4 | (10.7; 16.0) | 0.49 | – | – | – | – | – | – | – | – |
| OPN | 18.5 | (7.8; 19.6) | 17.1 | (14.6; 17.8) | 0.04* | 26/24 | 1.43 | (0.53; 3.84) | 0.48 | 26/17 | 0.75 | (0.41; 1.38) | 0.35 |
| VEGFR-1 | 8.2 | (1.3; 10.7) | 6.9 | (6.2; 9.3) | <0.01* | 28/58 | 0.84 | (0.35; 2.05) | 0.71 | 10/41 | 0.97 | (0.51; 1.84) | 0.93 |
| VEGFR-2 | 14.9 | (6.0; 16.7) | 13.7 | (12.4; 14.8) | <0.001* | 58/28 | 0.91 | (0.39; 2.16) | 0.84 | 36/14 | 0.60 | (0.28; 1.27) | 0.18 |
| IL-2 | 1.8 | (−1.7; 7.0) | 3.8 | (2.6; 6.7) | <0.001* | 28/56 | 0.83 | (0.36; 1.93) | 0.67 | 19/45 | 0.82 | (0.53; 1.29) | 0.39 |
| IL-13 | 0.8 | (−2.4; 4.0) | 0.5 | (−3.6; 2.9) | 0.94 | – | – | – | – | – | – | – | – |
| PDGF-bb | 8.0 | (4.9; 13.2) | 7.6 | (6.1; 9.7) | 0.56 | – | – | – | – | – | – | – | – |
| TNF | 1.1 | (−1.2; 8.4) | 0.3 | (0.3; 5.0) | 0.17 | – | – | – | – | – | – | – | – |
| PAI-1 | 14 | (11.8; 16.1) | 13.8 | (12.7; 15.1) | 0.37 | – | – | – | – | – | – | – | – |
| SDF-1a | 7.3 | (4.8; 11.0) | 7.4 | (6.5; 7.7) | 0.80 | – | – | – | – | – | – | – | – |
| IL-4 | −1.7 | (−4.1; 4.8) | −1.7 | (−1.7; 0.8) | <0.001* | 17/67 | 0.83 | (0.33; 2.11) | 0.70 | 14/14 | 1.13 | (0.57; 2.27) | 0.72 |
| IL-6 | 3.1 | (−1.3; 6.9) | 2.9 | (0.0; 4.7) | 0.67 | – | – | – | – | – | – | – | – |
| IL-8 | 3.3 | (0.7; 9.0) | 3.3 | (1.9; 5.4) | 0.97 | – | – | – | – | – | – | – | – |
| Eotaxin | 5.7 | (0.5; 8.2) | 5.2 | (3.8; 6.1) | 0.14 | – | – | – | – | – | – | – | – |
| G-CSF | 6.0 | (3.0; 9.9) | 5.6 | (3.2; 7.5) | 0.08 | – | – | – | – | – | – | – | – |
| VEGF | 5.4 | (−0.3; 9.3) | 3.1 | (−0.7; 5.6) | <0.001* | 45/39 | 0.87 | (0.38; 1.97) | 0.74 | 31/39 | 0.59 | (0.33; 1.07) | 0.08 |
| GRO-a | 5.3 | (3.6; 10.0) | 6.8 | (5.5; 7.9) | <0.001* | 40/44 | 1.42 | (0.62; 3.24) | 0.41 | 29/37 | 1.19 | (0.78; 1.82) | 0.42 |
| HGF | 8.1 | (4.0; 9.8) | 8.0 | (7.2; 8.5) | 0.60 | – | – | – | – | ||||
*
Significant.